Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient

Abed, Yacine; Schibler, Manuel; Checkmahomed, Liva; Carbonneau, Julie; Venable, Marie-Christine; Fage, Clément; Giannotti, Federica; Goncalves Cabecinhas, Ana Rita; Kaiser, Laurent; Boivin, Guy

doi:10.3851/IMP3344

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient
Authors		Abed, Yacine Schibler, Manuel Checkmahomed, Liva Carbonneau, Julie Venable, Marie-Christine Fage, Clément Giannotti, Federica Goncalves Cabecinhas, Ana Rita Kaiser, Laurent Boivin, Guy show all authors [1 - 10]
Published in		Antiviral therapy. 2019, vol. 24, no. 8, p. 581-587
Abstract		Neuraminidase (NA) inhibitors (NAIs), including oseltamivir and zanamivir, play an important therapeutic role against influenza infections in immunocompromised patients. In such settings, however, NAI therapy may lead to the emergence of resistance involving mutations within the influenza surface genes. The aim of this study was to investigate the evolution of NA and haemagglutinin (HA) genes of influenza A(H1N1)pdm09 virus in an immunocompromised patient receiving oseltamivir then zanamivir therapies.
Keywords		Aged — Antiviral Agents/administration & dosage/pharmacology/therapeutic use — Drug Resistance, Multiple, Viral — Enzyme Inhibitors/administration & dosage/pharmacology/therapeutic use — Hematopoietic Stem Cell Transplantation — Humans — Immunocompromised Host — Influenza A Virus, H1N1 Subtype/drug effects/genetics — Influenza, Human/drug therapy/virology — Male — Neuraminidase/antagonists & inhibitors — Oseltamivir/administration & dosage/pharmacology/therapeutic use — Transplant Recipients — Zanamivir/administration & dosage/pharmacology/therapeutic use
Identifiers		DOI: 10.3851/IMP3344 PMID: 32031540
Full text		Article (Published version) (165 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research groups		Groupe Laurent Kaiser (virologie clinique) (668) Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982)
Citation (ISO format)		ABED, Yacine et al. Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient. In: Antiviral Therapy, 2019, vol. 24, n° 8, p. 581-587. doi: 10.3851/IMP3344 https://archive-ouverte.unige.ch/unige:147186